Oruka Therapeutics (ORKA) Heads To Morgan Stanley, Is The Stock Fully Priced?

Oruka Therapeutics (ORKA) is set to present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026 in New York, putting its psoriasis-focused antibody pipeline in front of a broad investor audience.

Recent trading in Oruka Therapeutics has been choppy, with the share price falling 12.04% over the past 30 days despite an 11.22% 90 day share price return and a very large 1 year total shareholder return of around 7x. This suggests sentiment has cooled in the short term, even as longer term momentum and expectations around its psoriasis assets remain strong.

Scan beyond Oruka Therapeutics and explore additional high-momentum healthcare and biotech ideas using our curated list of 16 high quality undiscovered gems

The recent pullback in Oruka Therapeutics after a very strong 1 year run raises a simple issue: Are you seeing a reset in sentiment around the psoriasis pipeline or a fresh entry point into the same story at a lower price?

Preferred Price-to-Book Multiple of 5.7x: Is it justified?

Valuation on Oruka Therapeutics today leans heavily on its price-to-book profile, with the shares trading at a P/B of 5.7x against a last close of $94.96.

The P/B ratio compares the market value of the equity to the accounting value of net assets. For early stage biopharma like Oruka Therapeutics, investors often look at this measure because there is no meaningful revenue and the business is unprofitable, so earnings based metrics are not yet useful.

At 5.7x book value, the stock trades at a clear premium to the broader US biotech sector average of 2.3x. That signals investors are currently willing to pay more than twice the industry norm relative to net assets, even though the company reports a loss of $109.688m, has no revenue, is forecast to remain unprofitable and analysts expect earnings to decline on average 24.2% per year over the next 3 years.

Peer comparisons tell an extra story. Oruka Therapeutics screens as good value on P/B when stacked against a much higher 80.6x peer average. However, the same 5.7x level looks expensive versus the wider biotech industry, so the market is clearly pricing in a rich psoriasis and immunology pipeline while carrying meaningful execution and financing risk.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 5.7x (OVERVALUED).

Still, the Oruka Therapeutics story can crack if psoriasis trial data disappoints, or if fresh capital needs dilute existing holders at current levels.

Find out about the key risks to this Oruka Therapeutics narrative.

Next Steps

Given the mixed tone around Oruka Therapeutics, it makes sense to review the underlying data yourself and decide whether current pricing reflects the psoriasis opportunity or the embedded risks. Before leaning too far in either direction, review the 5 important warning signs

Looking for more Oruka Therapeutics sized opportunities?

If Oruka Therapeutics has you thinking about where the next big idea might come from, use this moment to line up a few more candidates before the market moves on.

• Target resilient potential by reviewing our 30 resilient stocks with low risk scores that aim to balance upside with tighter risk controls.
• Hunt for quality at a discount through the 35 high quality undervalued stocks, where fundamentals do more of the heavy lifting than hype.
• Stack your watchlist with steady payers using the 7 dividend fortresses that focus on higher yielding, income focused opportunities.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com